EUVIMEDEUVIMED entdecken
Crossref

The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer

Daiki Murata, Koichi Azuma, Yuuya Nishii, Kenta Murotani, Goushi Matama, Akihiko Kawahara, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino, Koichi Azuma

Chemotherapy · 2025

DOI: 10.1159/000543425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, 2025. Verfasst von Daiki Murata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Ghrelin, Cachexia, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Identifying the underlying mechanisms of immune checkpoint inhibitor resistance in patients with cachexia is a current challenge. Ghrelin is a peptide hormone that plays an important role in the metabolism of patients with cancer cachexia. Despite the importance of ghrelin in cancer cachexia, most previous studies on the subject have not distinguished between the forms of ghrelin.

Methods

We retrospectively screened patients with advanced or recurrent non-small cell lung cancer receiving PD-1/PD-L1 inhibitor monotherapy. Active and inactive ghrelin levels were measured in 100 patients with available plasma samples at immune checkpoint inhibitor initiation. Cancer cachexia was defined as weight loss of at least 5% during the past 6 months or weight loss of at least 2% with a BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GhrelinCachexiaCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesPrognosisAged, 80 and over

Stichwörter der Autor:innen

CachexiaGhrelinImmune checkpoint inhibitorNon-small cell lung cancerPD-L1

Substanzen

GhrelinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
  • Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan.
  • Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.
  • Cancer Vaccine and Immunotherapy Center and Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.

Zitieren

APA

Murata, D., Azuma, K., Nishii, Y., Murotani, K., Matama, G., Kawahara, A., Tokito, T., Sasada, T., Hoshino, T., & Azuma, K. (2025). The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. https://doi.org/10.1159/000543425

Vancouver

Murata D, Azuma K, Nishii Y, Murotani K, Matama G, Kawahara A, et al. The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. 2025. doi:10.1159/000543425

BibTeX
@article{Murata2025,
  author = {Murata, Daiki and Azuma, Koichi and Nishii, Yuuya and Murotani, Kenta and Matama, Goushi and Kawahara, Akihiko and Tokito, Takaaki and Sasada, Tetsuro and Hoshino, Tomoaki and Azuma, Koichi},
  title = {The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer},
  journal = {Chemotherapy},
  year = {2025},
  doi = {10.1159/000543425}
}
Kostenlos starten →